Open AccessVenlafaxine‐induced interstitial lung disease with COVID‐19 pandemic‐related depression
Author(s) -
Okazaki Akihito,
Kita Katsunao
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5941
Subject(s) - medicine , venlafaxine , discontinuation , depression (economics) , eosinophilic pneumonia , interstitial lung disease , pneumonia , pandemic , pneumonitis , intensive care medicine , covid-19 , disease , lung , diffuse alveolar damage , hypersensitivity pneumonitis , ards , anesthesia , respiratory disease , infectious disease (medical specialty) , antidepressant , acute respiratory distress , hippocampus , economics , macroeconomics
Venlafaxine‐associated pulmonary toxicity is rare, with only a few reports of pneumonitis, eosinophilic pneumonia, and asthma. We report a case of venlafaxine‐induced interstitial lung disease in a patient with coronavirus disease 2019 pandemic‐related depression. Chest imaging findings improved after discontinuation of venlafaxine and treatment with corticosteroids.